Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aurinia Pharmaceuticals Inc.
< Previous
1
2
3
Next >
Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office
January 24, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results
January 06, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals
January 03, 2023
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
November 30, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results
November 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022
October 28, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022
October 27, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022
September 20, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis
September 19, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results
August 04, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 01, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review
July 26, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022
July 25, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe
July 22, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance
July 14, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations
June 03, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress
May 20, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress
May 16, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports First Quarter 2022 Financial and Operational Results
May 10, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
May 06, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022
May 02, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis
April 19, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings
April 04, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates
February 28, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021
February 09, 2022
From
Aurinia Pharmaceuticals Inc.
Via
Business Wire
Tickers
AUPH
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.